Vorinostat Completed Phase 3 Trials for Multiple Myeloma (MM) Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00773747Study of Vorinostat (MK-0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma (MK-0683-088 AMN)